Evidence map›Paper›PMID 39908060›Full record

ArticleChemMedChem2025

Design and Synthesis of

Sacha Bodin, Santo Previti, Emmanuelle Jestin, Emmanuelle Rémond, Delphine Vimont, Frédéric Lamare, Imade Ait-Arsa, Elif Hindié, Florine Cavelier, Clément Morgat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Design and Synthesis ofChemMedChem · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sacha BodinUniversity of Bordeaux, CNRS, EPHE, INCIA UMR 5287, F-33400, Talence, France.ORCID https://orcid.org/0000-0001-7331-8536
Santo PrevitiPôle Chime Balard, IBMM, UMR 5247, CNRS, Université Montpellier, ENSCM, F-34293, Montpellier, France.
Emmanuelle JestinGIP CYROI - Cyclotron Réunion Océan Indien, F-97490, Saint Clotilde, France.
Emmanuelle RémondPôle Chime Balard, IBMM, UMR 5247, CNRS, Université Montpellier, ENSCM, F-34293, Montpellier, France.
Delphine VimontUniversity of Bordeaux, CNRS, EPHE, INCIA UMR 5287, F-33400, Talence, France.
Frédéric LamareUniversity of Bordeaux, CNRS, EPHE, INCIA UMR 5287, F-33400, Talence, France.
Imade Ait-ArsaGIP CYROI - Cyclotron Réunion Océan Indien, F-97490, Saint Clotilde, France.
Elif HindiéUniversity of Bordeaux, CNRS, EPHE, INCIA UMR 5287, F-33400, Talence, France.
Florine CavelierPôle Chime Balard, IBMM, UMR 5247, CNRS, Université Montpellier, ENSCM, F-34293, Montpellier, France.ORCID https://orcid.org/0000-0001-5308-6416
Clément MorgatUniversity of Bordeaux, CNRS, EPHE, INCIA UMR 5287, F-33400, Talence, France.ORCID https://orcid.org/0000-0002-9432-9223

Funding

RRI NEWMOON Impulsion of Bordeaux University
6 · The paper itself

Abstract

Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS

Indexed as

Drug DesignGallium RadioisotopesPeptidesRadiopharmaceuticalsReceptors, BombesinReceptors, NeurotensinDimerizationHT29 CellsHumansMolecular StructureGallium-68Gallium Radioisotopesneurotensin type 1 receptorPeptidesRadiopharmaceuticalsReceptors, BombesinReceptors, NeurotensinBombesinGRPRHeterodimersNeurotensinNTS1PET imaging

Identifiers

PMID39908060
PMCPMC12058244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.